Nancy E. Lane, M.D. View profile as PDF

Nancy E. Lane

Clinical/Research Interests

Nancy E. Lane, MD is an Endowed Professor of Medicine, Rheumatology, and Aging Research, Director for the Center for Musculoskeletal Health, Director of the K12 NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH), and Principal Investigator of the NIH funded Program on Sex Differences in Musculoskeletal Diseases Across the Lifespan at the University of California at Davis School of Medicine where she has served for the past 8 years.

Dr. Lane is an internationally recognized scientist in the fields of both osteoporosis and osteoarthritis. Her translational research team has been instrumental in defining the role of glucocorticoids in bone fragility including their effects on cell stress and vulnerable cell populations including osteocytes. As a faculty member at the University of California at San Francisco, she pioneered a seminal clinical trial to demonstrate that daily injections of the hormone PTH could reverse glucocorticoid induced osteoporosis. After transitioning to U.C. Davis, she a developed a novel compound to direct stem cells to the bone to grow new bone and treat osteoporosis. In addition she has uncovered novel genetic variations that predispose individuals to osteoarthritis and has studied novel treatments for osteoarthritis. She organized and directs an NIH funded junior faculty grant writing workshop that has taught over 300 junior faculty in musculoskeletal medicine grant writing skills that has resulted in a 45% success rate in applicants receiving research grants (2006-present).

Dr. Lane has been recognized by the University, her medical residents, subspecialty fellows, and by her faculty peers as an outstanding mentor with the UC Davis Dean's Award for Scientific Mentoring (2008). Her research accomplishments have been recognized by the UC Davis School of Medicine Dean's Team Science Award (2012), the American College of Rheumatology for the Oscar Gluck Memorial Lecture for outstanding work in Osteoporosis (2011), the Remodeling in Bone “RIB Award” by the International Society of Bone and Mineral Research (2012), her election as a Master of the American College of Physicians (2012) and David Trentham Lectureship and Women in Medicine Lectureship at Harvard Medical School (2013).. She is also recipient of the Bone and Joint Decade Outstanding Achievement Award for developing a mentoring program in grant writing (2009).

Dr. Lane was President of the Board of the United States Bone and Joint Decade (2006-2008), co-led the International Bone and Joint Decade Conference in Washington DC (2010),was elected and serves on the council of the American Society of Bone and Mineral Research (2010-2013), and the Orthopedic Research Society.

Dr. Lane is on the editorial boards of Nature Reviews Rheumatology, Rheumatology (Associate Editor), Seminars in Arthritis and Rheumatism (Associate Editor), Co-editor Arthritis and Rheumatism (2005-2010), Journal of Rheumatology, She was elected to the Association of American Physicians (2006), has been named Best Doctors in America annually since 2004, and continues to have an active rheumatology practice.


Endowed Professor of Medicine and Rheumatology, Director of Center for Musculoskeletal Health


Internal Medicine, Rheumatology, Allergy and Clinical Immunology


UC San Francisco School of Medicine
San Francisco, California
M.D. 1980

UC Davis
Davis, California
B.S. 1976


Mount Zion Hospital and Medical Center
San Francisco, California


Palo Alto Veterans Administration Hospital and Stanford University Medical Center
Stanford, California

Board Certifications:

American Board of Internal Medicine, Rheumatology, 1986
American Board of Internal Medicine, 1983

Select Recent Publications:

Lane NE, Corr M. Osteoarthritis in 2016: Anti-NGF treatments for pain – two steps forward, one step back? Nat Rev Rheumatol. 2017 Jan 25;13(2):76-78.

Mohan G, Lay YE, Berka H, Ringwood L, Kot A, Chen H, Yao W, Lane NE. A novel hybrid compound LLP2A-Ale both prevented and rescued the osteoporotic phenotype in a mouse model of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2017 Jan;100(1):67-79.

Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Uña CR, Adachi JD, Lems WF, Cooper C, Lane NE. Biologic Therapies and Bone Loss in Rheumatoid Arthritis. IOF Chronic Inflammation and Bone Structure (CIBS) Working Group. Osteoporosis Int. 2017 Feb;28(2):429-446.

Lane NE, Shidara K, Wise BL. Osteoarthritis Year in Review 2016: Clinical.  Osteoarthritis Cartilage. 2017 Feb;25(2):209-215.

Hiatt RA, Bailer J, Bascom R, Churchill L, Crump K, Foster Riley M, Briedman DB, Gold D, Goldfrank L, Lane NE, Lippmann M, Mittleman M, Needleman P, Phale R, Shin H. Controlled Human Inhalation-Exposure Studies at EPA. Committee on Assessing Toxicologic Risks to Human Subjects Used in Controlled Exposure Studies of Environmental Pollutants. The National Academies of Sciences, Engineering, Medicine. March 2017.

Chang RW, Fitzgerald K, Lane NE, Mikdashi J. Peer Reviewers. Treatment of Osteoarthritis of the Knee: An Update Review. Comparative Effectiveness Review No. 190, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. May 2017.

Lane NE, Corr M, Baer N, Yazici Y. Wnt signaling in osteoarthritis: A 2017 update. Current Treat Options in Rheum, June 2017; (3):101-111.

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017 Aug;69(8):1521-1537.Epub 2017 Jun 6. Review. Erratum in: Arthritis Rheumatol. 2017 Nov;69(11):2246.

Katzman WB, Vittinghoff E, Lin F, Schafer A, Long RK, Wong S, Gladin A, Fan B, Allaire B, Kado DM, Lane NE. Targeted spine strengthening exercise and posture training program to reduce hyperkyphosis in older adults: results from the study of hyperkyphosis, exercise, and function (SHEAF) randomized controlled trial. Osteoporos Int. 2017 Oct;28(10):2831-2841.

Stern AR, Yao X, Wang Y, Berhe A, Dallas M, Johnson ML, Yao W, Kimmel DB, Lane NE. Effect of osteoporosis treatment agents on the cortical bone osteocyte microenvironment in adult estrogen-deficient, osteopenic rats. Bone Rep. 2018 Feb 26;8:115-124. eCollection 2018 Jun.

Dubrovsky AM, Lim MJ, Lane NE. Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton. Calcif Tissue Int. 2018 May;102(5):607-618.

Christiansen BA, Harrison SL, Fink HA, Lane NE. Study of Osteoporotic Fractures Research Group. Incident fracture is associated with a period of accelerated loss of hip BMD: the Study of Osteoporotic Fractures. Osteoporos Int. 2018 Jul 10.

To see if Nancy E. Lane is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).